Sanofi and Regeneron Announce 18Month Results of ODYSSEY LONG TERM Trial with Praluent TM alirocumab Published in The New England Journal of Medicine Robust and consistent LDLC lowering demonstrated with PraluentTM in largest doubleblind placebocontr...
↧